Boehringer Ingelheim and Tessellate Bio Forge €500M Deal to Develop First-in-Class Oral Cancer Therapies Targeting ALT-Dependent Tumors

Boehringer Ingelheim and Tessellate Bio, a precision oncology company with a focus on developing novel synthetic lethality approaches, have entered into ...

April 23, 2025 | Wednesday | News
Intuitive Research Confirms Robotic-Assisted Surgery Expands Access to High-Quality Care in Medically Remote Regions

  Intuitive , a global leader in minimally invasive care and the pioneer of robotic-assisted surgery (RAS),  announced the publication of two st...

April 18, 2025 | Friday | Reports
Lecanemab Becomes First Approved Disease-Modifying Therapy for Early Alzheimer’s in the EU

In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild de...

April 16, 2025 | Wednesday | News
Sanofi Expands Respiratory Pipeline With Promising Asthma Data and New COPD Study Plans

Sanofi’s respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD New phase 2 data for amlitelimab show ...

April 15, 2025 | Tuesday | News
New Study Links SARS-CoV-2 Spike Protein Region to Autoantibody Production Potentially Driving Long COVID

 Long COVID or post COVID-19 syndrome, is a clinical entity observed in certain patients wherein symptoms of illness persist for at least several week...

April 10, 2025 | Thursday | News
Serina Therapeutics Raises $5M to Advance Novel Parkinson’s Therapy Toward Phase 1 Trial

Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform&tra...

April 09, 2025 | Wednesday | News
HNL Lab Medicine Partners with Northampton County to Offer Free Lead Testing for Children

HNL Lab Medicine, in partnership with Northampton County, is making it easier for families to access lead testing for children. Lead exposure remains a ser...

April 08, 2025 | Tuesday | News
Amgen’s UPLIZNA Receives FDA Approval as First Treatment for IgG4-Related Disease, Cutting Flare Risk by 87%

Breakthrough CD19+ B-Cell Targeted Therapy Delivered an 87% Reduction in the Risk of Flares Versus Placebo  UPLIZNA Shown to De...

April 04, 2025 | Friday | News
Singapore’s NUS Integrates AI and 3D Bioprinting to Transform Personalised Gum Tissue Grafts

Artificial intelligence streamlines the optimisation of bioprinting parameters for oral soft tissue grafts, reducing time and resourc...

April 04, 2025 | Friday | Reports
Novo Nordisk’s Semaglutide 2.4 mg Linked to 57% Reduction in Cardiovascular Events in Real-World SCORE Study

Novo Nordisk announced new findings from the retrospective, observational SCORE study, demonstrating that treatment with semaglutide 2.4 mg was associate...

March 31, 2025 | Monday | News
Medtronic’s Evolut TAVR Demonstrates Durable Outcomes at Five Years in Low-Risk Patients with Severe Aortic Stenosis

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, announced late-breaking data on five-year outcomes from the Evolut Low Risk Trial. D...

March 31, 2025 | Monday | News
Lilly’s Lepodisiran Shows 94% Reduction in Lipoprotein(a) in Phase 2 Trial, Advancing Hope for Genetic Heart Risk Treatment

Eli Lilly and Company announced positive Phase 2 results for lepodisiran, an investigational small interfering RNA (siRNA) therapy designed to lower the ...

March 31, 2025 | Monday | News
Merck and Hengrui Pharma Forge $1.97 Billion Global Partnership to Advance Novel Lp(a) Inhibitor for Cardiovascular Disease

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Jiangsu Hengrui Pharmaceuticals Co., Ltd. (“Hengrui Pharma”), a ...

March 26, 2025 | Wednesday | News
B. Braun Launches 3 g Cefazolin in DUPLEX® for Surgical Infection Prevention

B. Braun Medical Inc. (B. Braun), a leader in smart infusion therapy and pain management, announced the launch of its new Cefazolin 3 g, the latest cefazol...

March 25, 2025 | Tuesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close